Legacy Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$252K	Buy	+508	New	+$225K	0.02%	283
2025 Q2	–	Sell	-951	Closed	-$461K	–	398
2025 Q1	$461K	Buy	951 +62	+7%	+$28.9K	0.05%	272
2024 Q4	$358K	Buy	889 +99	+13%	+$45.9K	0.03%	288
2024 Q3	$367K	Buy	790 +241	+44%	+$116K	0.04%	273
2024 Q2	$257K	Buy	549 +2	+0.4%	+$868	0.03%	273
2024 Q1	$229K	Buy	547 +33	+6%	+$13.9K	0.03%	285
2023 Q4	$209K	Buy	+514	New	+$190K	0.03%	293
2019 Q2	–	Sell	-8,000	Closed	-$1.47M	–	425
2019 Q1	$1.47M	Buy	+8,000	New	+$1.48M	0.48%	49
2017 Q4	–	Sell	-67	Closed	-$10K	–	433
2017 Q3	$10K	Buy	+67	New	+$10.1K	0.01%	225

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Legacy Advisors's VRTX Position: Q2 2026 in Review

Legacy Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 508 shares worth $252K. The stake represents 0.02% of the portfolio and ranks #283 among its holdings. This is a return to the name: Legacy Advisors previously reported a position in VRTX as recently as Q1 2025.

Legacy Advisors first reported a position in VRTX in Q3 2017 and has held it in 9 quarters since. The position peaked at $1.47M in Q1 2019. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Legacy Advisors held 508 shares of Vertex Pharmaceuticals worth $252K as of Q2 2026.
Vertex Pharmaceuticals was a new Legacy Advisors position in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of Legacy Advisors's portfolio in Q2 2026, its #283 holding.
Legacy Advisors first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 9 quarters since.
Legacy Advisors's Vertex Pharmaceuticals position peaked at $1.47M in Q1 2019.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Legacy Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.